Description
This blend combines two research compounds from different classes in a single injectable vial. One is Retatrutide (LY3437943), a triple-incretin agonist that simultaneously activates GLP-1, GIP and glucagon receptors. The other is Tesamorelin, a synthetic analog of growth-hormone-releasing hormone (GHRH). Retatrutide addresses the incretin axis across three receptor systems at once, with the glucagon component associated in research with increased energy expenditure and greater lipid breakdown. Tesamorelin acts at an entirely different site: as a selective agonist at the GHRH receptor of the pituitary, stimulating the body’s own pulsatile growth hormone release rather than supplying GH directly.
Both active ingredients are injectable peptides in their clinically studied form. That is exactly how this blend ships: as a freeze-dried powder (lyophilizate) that you reconstitute with bacteriostatic water and administer subcutaneously. This matches the route on which the published studies are based. What still needs framing honestly: there are no robust clinical data on precisely this Reta-plus-Tesamorelin combination in one vial. The evidence stems from the individual compounds. The two have very different dosing magnitudes, which makes the fixed 1:1 mix experimental.
The core research findings stem from the injectable individual compounds. For Retatrutide, phase 2 data showed body weight reductions of up to 24.2 percent after 48 weeks in study models with subjects who had obesity. They also showed reductions in liver fat content in MASLD research. For Tesamorelin, pooled phase 3 studies documented significant reductions in visceral adipose tissue while preserving subcutaneous fat, alongside an increase in IGF-1. These findings apply to the respective subcutaneous mono-application, not to the combination.
You receive this blend as a research compound in 10 vials of 20 mg per vial (10 mg Retatrutide plus 10 mg Tesamorelin), as a lyophilizate for reconstitution. The format is intended for experimental research approaches.
This information is for research and educational purposes only. Not medical advice.
Studies
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial - NEJM 2023: Phase 2 data on the Retatrutide component (triple agonist), including the documented body weight reductions (subcutaneous).
- Effects of tesamorelin (TH9507), a GHRH analog, in patients with excess abdominal fat - pooled phase 3 analysis - J Clin Endocrinol Metab 2010: Pooled phase 3 data on the Tesamorelin component, visceral fat reduction and IGF-1 increase (subcutaneous).
- Efficacy and safety of tesamorelin - randomized double-blind trial - AIDS 2024: Recent randomized study with MRI quantification of visceral and hepatic fat under subcutaneous tesamorelin.
